M. Mendila

发表

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

A. López-Guillermo, U. Jaeger, S. Kvaløy, 2006, The Lancet. Oncology.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

A. Berrebi, H. Döhner, G. Fingerle-Rowson, 2010, The Lancet.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Andrew Lister, Anne Sonet, Hervé Tilly, 2011, The Lancet.

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.

B. Coiffier, R. Foà, H. Burger, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

P. Ganly, T. Robak, C. Geisler, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tuberculosis cutis colliquativa during long-term immunosuppressive therapy for rheumatoid arthritis.

J. Ockenga, P. Kirschner, M. Mendila, 1997, Arthritis and rheumatism.

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

E. Kimby, B. Coiffier, A. Belch, 2007 .

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

H. Döhner, G. Fingerle-Rowson, M. Hallek, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

H. Döhner, U. Jäger, M. Hallek, 2009 .

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

M. Hallek, S. Stilgenbauer, D. Winkler, 2011 .

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

H. Döhner, P. Lichter, G. Fingerle-Rowson, 2010 .

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

H. Döhner, G. Fingerle-Rowson, M. Hallek, 2010 .

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

H. Döhner, U. Jäger, M. Hallek, 2008 .

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

P. Ganly, T. Robak, C. Geisler, 2008 .

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

A. Berrebi, U. Jaeger, H. Döhner, 2008 .

[Rhabdomyolysis in antiretroviral therapy with Lamivudin].

M. Mendila, M. Stoll, R. Schmidt, 1997, Deutsche medizinische Wochenschrift.

Highly active antiretroviral therapy

I. Schedel, M. Mendila, G. Behrens, 1998, The Lancet.

Immunologic and virologic studies in long-term nonprogressors with HIV-1 infection.

R. Jacobs, H. Heiken, M. Mendila, 1999, European journal of medical research.

The effect of negative intraarticular pressure and rotator cuff force on glenohumeral translation during simulated active elevation.

N. Wülker, M. Mendila, C. Hurschler, 2000, Clinical biomechanics.

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

H. Döhner, G. Fingerle-Rowson, M. Hallek, 2011 .